STOCK TITAN

Cabaletta Bio to Present at the 20th Annual Needham Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Cabaletta Bio is a clinical-stage biotechnology firm focused on engineered T cell therapies for patients with B cell-mediated autoimmune diseases. On April 14, 2021, at 3:00 p.m. ET, CEO Steven Nichtberger will participate in a fireside chat at the 20th Annual Needham Healthcare Conference. The live webcast will be accessible on the company’s website and will remain available for replay for 90 days. The lead product candidate, DSG3-CAART, targets mucosal pemphigus vulgaris and has received Fast Track Designation from the FDA.

Positive
  • None.
Negative
  • None.

PHILADELPHIA, April 07, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in a fireside chat at the 20th Annual Needham Healthcare Conference on Wednesday, April 14, 2021 at 3:00 p.m. ET.

A live webcast of the fireside chat will be available on the News and Events section of the company’s website at www.cabalettabio.com. Following the presentation, a replay of the webcast will be available on the website for 90 days.

About Cabaletta Bio
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA) platform, in combination with Cabaletta’s proprietary technology, utilizes Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company’s lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. For more information about the clinical trial, please see www.clinicaltrials.gov. The Company’s lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis. For more information, visit www.cabalettabio.com.

Contacts:
Anup Marda
Chief Financial Officer
investors@cabalettabio.com

Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah.mccabe@sternir.com


FAQ

What is the focus of Cabaletta Bio?

Cabaletta Bio is focused on developing engineered T cell therapies for B cell-mediated autoimmune diseases.

When is Steven Nichtberger speaking at the Needham Healthcare Conference?

Steven Nichtberger will speak at the 20th Annual Needham Healthcare Conference on April 14, 2021, at 3:00 p.m. ET.

How can I watch the Cabaletta Bio fireside chat?

The fireside chat can be viewed live on Cabaletta Bio's website, with a replay available for 90 days.

What is DSG3-CAART and its clinical status?

DSG3-CAART is Cabaletta Bio's lead product candidate, currently evaluated in the DesCAARTes™ phase 1 clinical trial for mucosal pemphigus vulgaris.

What FDA designation has DSG3-CAART received?

DSG3-CAART has received Fast Track Designation from the FDA.

Cabaletta Bio, Inc.

NASDAQ:CABA

CABA Rankings

CABA Latest News

CABA Stock Data

188.56M
48.85M
3.1%
105.81%
7.74%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
PHILADELPHIA